Protocols: Editas recruits a Bristol-Myers vet as CSO; Eli Lilly gets a dubious honor for Alzheimer's drug; Voyager in the spotlight
Cambridge, MA-based gene editing stalwart Editas has recruited a Bristol-Myers vet for the CSO’s job. Charles Albright moves in after a stint as VP of genetically defined diseases and genomics at Bristol-Myers.
Eli Lilly got a fast track designation for its BACE drug for Alzheimer’s, AZD3293. The designation, though, signifies little of anything significant. Fast track designations come fast and easy in this branch of R&D, while research projects for Alzheimer’s are long, arduous and expensive. They are also usually unsuccessful. Lilly got this drug from AstraZeneca, after its own BACE drug was torpedoed by toxicity issues.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
